Eli Lilly and (NYSE:LLY) Upgraded at StockNews.com

Eli Lilly and (NYSE:LLY – Get Rating) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday.

LLY has been the subject of several other research reports. UBS Group raised their target price on shares of Eli Lilly and from $447.00 to $498.00 and gave the stock a “buy” rating in a report on Wednesday. Wells Fargo & Company raised their target price on shares of Eli Lilly and from $375.00 to $440.00 in a report on Friday, April 28th. Barclays raised their target price on shares of Eli Lilly and from $400.00 to $420.00 in a report on Monday, May 1st. Morgan Stanley lifted their price objective on shares of Eli Lilly and from $478.00 to $507.00 in a report on Monday, May 15th. Finally, Truist Financial lifted their price objective on shares of Eli Lilly and from $421.00 to $430.00 in a report on Friday, April 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $422.19.

Eli Lilly and Stock Performance

Shares of NYSE:LLY opened at $427.31 on Friday. Eli Lilly and has a 52 week low of $283.11 and a 52 week high of $454.95. The stock has a market capitalization of $405.63 billion, a P/E ratio of 67.93, a PEG ratio of 2.25 and a beta of 0.37. The firm has a fifty day simple moving average of $386.14 and a two-hundred day simple moving average of $362.10. The company has a quick ratio of 1.02, a current ratio of 1.30 and a debt-to-equity ratio of 1.67.

Eli Lilly and (NYSE:LLY – Get Rating) last issued its quarterly earnings data on Thursday, April 27th. The company reported $1.62 EPS for the quarter, missing analysts’ consensus estimates of $1.73 by ($0.11). The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.87 billion. Eli Lilly and had a return on equity of 61.42% and a net margin of 20.54%. The business’s quarterly revenue was down 10.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.62 earnings per share. On average, analysts expect that Eli Lilly and will post 8.78 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and

In other news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $435.29, for a total value of $261,174.00. Following the transaction, the chief accounting officer now owns 5,978 shares of the company’s stock, valued at approximately $2,602,163.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction that occurred on Friday, March 31st. The shares were sold at an average price of $342.01, for a total transaction of $70,112,050.00. Following the sale, the insider now owns 102,543,810 shares of the company’s stock, valued at approximately $35,071,008,458.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $435.29, for a total transaction of $261,174.00. Following the sale, the chief accounting officer now directly owns 5,978 shares in the company, valued at approximately $2,602,163.62. The disclosure for this sale can be found here. Insiders have sold a total of 1,303,605 shares of company stock valued at $497,320,473 in the last 90 days. Insiders own 0.13% of the company’s stock.

Institutional Trading of Eli Lilly and

Several large investors have recently bought and sold shares of the stock. Y.D. More Investments Ltd acquired a new stake in Eli Lilly and during the 4th quarter valued at approximately $26,000. Silicon Valley Capital Partners acquired a new stake in Eli Lilly and during the 1st quarter valued at approximately $25,000. Bogart Wealth LLC lifted its stake in Eli Lilly and by 193.3% during the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock valued at $30,000 after acquiring an additional 58 shares during the period. Destiny Wealth Partners LLC lifted its stake in Eli Lilly and by 97.8% during the 4th quarter. Destiny Wealth Partners LLC now owns 91 shares of the company’s stock valued at $33,000 after acquiring an additional 45 shares during the period. Finally, Laffer Tengler Investments acquired a new stake in Eli Lilly and during the 1st quarter valued at approximately $33,000. Hedge funds and other institutional investors own 82.13% of the company’s stock.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.